Regenxbio Inc (RGNX)

$8.57 -0.51 (-5.62%)
Market Cap 442.32M
Revenue (ttm) 170.44M
Net Income (ttm) -193.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -113.75%
Debt to Equity Ratio 0.00
Volume 1,058,100
Avg Vol 1,025,422
Day's Range N/A - N/A
Shares Out 51.61M
Stochastic %K 20%
Beta 1.08
Analysts Strong Sell
Price Target $29.25

Company Profile

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 552 8181
Address:
9804 Medical Center Drive, Rockville, United States
Ml55totoag
Ml55totoag Mar. 14 at 4:03 PM
$RGNX another trail of money to rgnx door.
1 · Reply
sentinelles
sentinelles Mar. 14 at 5:38 AM
$RGNX biotechnology company Regenxbio
0 · Reply
Ml55totoag
Ml55totoag Mar. 14 at 2:09 AM
$RGNX fda official still attacking qure. Who knows we are next. This is terrible!
0 · Reply
biotechdeepvalue
biotechdeepvalue Mar. 13 at 10:55 PM
$RGNX let’s talk revenue from patents — future royalties from Itvisma + the damage or royalties from the SRPT infringement case… surely that alone would value this company at $2B at least
1 · Reply
jerzypawlik
jerzypawlik Mar. 13 at 6:48 PM
$RGNX loaded 20k shares. I feel very good about the near future. I was also in CAPR however I think we have better shot to get the FDA approval sooner.
0 · Reply
Cashmoneyt
Cashmoneyt Mar. 13 at 6:25 PM
$RGNX I will never understand why this stock goes down so much on no news and doesn’t even react to positive news.
2 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Mar. 13 at 5:54 PM
$RGNX https://www.biospace.com/fda/prasads-request-to-remain-anonymous-shines-light-on-fdas-transparency-problem
0 · Reply
BRITLS
BRITLS Mar. 13 at 4:25 PM
$RGNX following capr?
1 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Mar. 13 at 3:55 PM
$RGNX filled the gap and AFAIK prasad is not returning seems like a compelling buy
0 · Reply
Ml55totoag
Ml55totoag Mar. 13 at 3:33 PM
$RGNX 2c and 2f are no good theyll probably end up in wheelchair. 2g iis nothing short of miracle. This kid can bike and play soccer, normal kid, like duchenne is just a bad dream.
1 · Reply
Latest News on RGNX
Regenxbio Reports Duchenne Gene Therapy Progress As Stock Slides On Mixed Signals

Mar 11, 2026, 2:19 PM EDT - 4 days ago

Regenxbio Reports Duchenne Gene Therapy Progress As Stock Slides On Mixed Signals

Regenxbio's Duchenne gene therapy shows improved muscle function in trial

Mar 11, 2026, 12:00 PM EDT - 4 days ago

Regenxbio's Duchenne gene therapy shows improved muscle function in trial

REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

Mar 11, 2026, 11:45 AM EDT - 4 days ago

REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

FDA reversals leave investors worrying about the fates of other experimental drugs

Mar 6, 2026, 11:33 AM EST - 9 days ago

FDA reversals leave investors worrying about the fates of other experimental drugs

DNLI MRNA WVE

REGENXBIO Inc. (RGNX) Q4 2025 Earnings Call Transcript

Mar 5, 2026, 5:45 PM EST - 9 days ago

REGENXBIO Inc. (RGNX) Q4 2025 Earnings Call Transcript

RGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: SUEWALLST

Mar 5, 2026, 2:25 PM EST - 10 days ago

RGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: SUEWALLST

REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Mar 5, 2026, 7:05 AM EST - 10 days ago

REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Mar 4, 2026, 7:05 AM EST - 11 days ago

REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

REGENXBIO, Inc. Stockholders Have Rights - Stockholders Who Lost Money Investing in RGNX Should Contact Robbins LLP for Information About Recovering Their Losses

Mar 2, 2026, 5:58 PM EST - 12 days ago

REGENXBIO, Inc. Stockholders Have Rights - Stockholders Who Lost Money Investing in RGNX Should Contact Robbins LLP for Information About Recovering Their Losses

REGENXBIO to Participate in Upcoming Investor Conferences

Mar 2, 2026, 7:05 AM EST - 13 days ago

REGENXBIO to Participate in Upcoming Investor Conferences

REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Feb 25, 2026, 7:05 AM EST - 18 days ago

REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2026 in REGENXBIO Lawsuit - RGNX

Feb 24, 2026, 9:00 AM EST - 19 days ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2026 in REGENXBIO Lawsuit - RGNX

Regenxbio: Cautiously Bullish After FDA Setbacks

Feb 13, 2026, 6:07 AM EST - 4 weeks ago

Regenxbio: Cautiously Bullish After FDA Setbacks

FDA Rejection Clouds Path For REGENXBIO's Rare Disease Treatment

Feb 10, 2026, 8:51 AM EST - 4 weeks ago

FDA Rejection Clouds Path For REGENXBIO's Rare Disease Treatment

US FDA declines to approve Regenxbio's rare disease drug

Feb 9, 2026, 4:13 PM EST - 4 weeks ago

US FDA declines to approve Regenxbio's rare disease drug

REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II

Feb 9, 2026, 4:05 PM EST - 4 weeks ago

REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II

RGNX Investors Have Opportunity to Join REGENXBIO Inc. Fraud Investigation with the Schall Law Firm

Feb 3, 2026, 3:06 PM EST - 5 weeks ago

RGNX Investors Have Opportunity to Join REGENXBIO Inc. Fraud Investigation with the Schall Law Firm

Investigation into Regenxbio: Questions Arise Over Disclosure Completeness Prior to FDA Action

Jan 29, 2026, 6:06 PM EST - 6 weeks ago

Investigation into Regenxbio: Questions Arise Over Disclosure Completeness Prior to FDA Action

FDA Clinical Hold Knocks REGENXBIO Stock

Jan 28, 2026, 12:31 PM EST - 6 weeks ago

FDA Clinical Hold Knocks REGENXBIO Stock

US FDA places clinical hold on Regenxbio's gene therapy trials

Jan 28, 2026, 7:46 AM EST - 6 weeks ago

US FDA places clinical hold on Regenxbio's gene therapy trials

REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs

Jan 28, 2026, 7:30 AM EST - 6 weeks ago

REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs

REGENXBIO: Key FDA Decision On Hunter Syndrome Just Weeks Away

Jan 27, 2026, 8:28 AM EST - 6 weeks ago

REGENXBIO: Key FDA Decision On Hunter Syndrome Just Weeks Away

REGENXBIO Inc. (RGNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 4:25 PM EST - 2 months ago

REGENXBIO Inc. (RGNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program

Jan 11, 2026, 3:00 PM EST - 2 months ago

REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program

REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 7:05 AM EST - 3 months ago

REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

REGENXBIO to Participate in Upcoming Investor Conference

Nov 25, 2025, 7:05 AM EST - 3 months ago

REGENXBIO to Participate in Upcoming Investor Conference

REGENXBIO Inc. (RGNX) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:16 PM EST - 4 months ago

REGENXBIO Inc. (RGNX) Q3 2025 Earnings Call Transcript

REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights

Nov 6, 2025, 7:05 AM EST - 4 months ago

REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights

REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program

Oct 30, 2025, 7:05 AM EDT - 4 months ago

REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights

Oct 29, 2025, 7:05 AM EDT - 4 months ago

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights

REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting

Oct 9, 2025, 7:05 AM EDT - 5 months ago

REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting

REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD

Oct 6, 2025, 7:05 AM EDT - 5 months ago

REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD

REGENXBIO Announces Presentation at the World Muscle Society

Sep 29, 2025, 7:05 AM EDT - 5 months ago

REGENXBIO Announces Presentation at the World Muscle Society

Regenxbio: Poised For Breakthrough With RGX-121 Gene Therapy In Hunter Syndrome

Sep 9, 2025, 6:12 AM EDT - 6 months ago

Regenxbio: Poised For Breakthrough With RGX-121 Gene Therapy In Hunter Syndrome

REGENXBIO Inc. (RGNX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 2:05 PM EDT - 6 months ago

REGENXBIO Inc. (RGNX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Regenxbio: Remains A "Buy Rating" Despite BLA Review Delay Of RGX-121 For Hunter Syndrome

Sep 6, 2025, 8:29 AM EDT - 6 months ago

Regenxbio: Remains A "Buy Rating" Despite BLA Review Delay Of RGX-121 For Hunter Syndrome

REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II

Sep 5, 2025, 7:05 AM EDT - 6 months ago

REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II

FDA Extends Decision Date On Regenxbio's Gene Therapy Into Next Year

Aug 19, 2025, 12:01 PM EDT - 7 months ago

FDA Extends Decision Date On Regenxbio's Gene Therapy Into Next Year

REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II

Aug 18, 2025, 5:00 PM EDT - 7 months ago

REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II

Ml55totoag
Ml55totoag Mar. 14 at 4:03 PM
$RGNX another trail of money to rgnx door.
1 · Reply
sentinelles
sentinelles Mar. 14 at 5:38 AM
$RGNX biotechnology company Regenxbio
0 · Reply
Ml55totoag
Ml55totoag Mar. 14 at 2:09 AM
$RGNX fda official still attacking qure. Who knows we are next. This is terrible!
0 · Reply
biotechdeepvalue
biotechdeepvalue Mar. 13 at 10:55 PM
$RGNX let’s talk revenue from patents — future royalties from Itvisma + the damage or royalties from the SRPT infringement case… surely that alone would value this company at $2B at least
1 · Reply
jerzypawlik
jerzypawlik Mar. 13 at 6:48 PM
$RGNX loaded 20k shares. I feel very good about the near future. I was also in CAPR however I think we have better shot to get the FDA approval sooner.
0 · Reply
Cashmoneyt
Cashmoneyt Mar. 13 at 6:25 PM
$RGNX I will never understand why this stock goes down so much on no news and doesn’t even react to positive news.
2 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Mar. 13 at 5:54 PM
$RGNX https://www.biospace.com/fda/prasads-request-to-remain-anonymous-shines-light-on-fdas-transparency-problem
0 · Reply
BRITLS
BRITLS Mar. 13 at 4:25 PM
$RGNX following capr?
1 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Mar. 13 at 3:55 PM
$RGNX filled the gap and AFAIK prasad is not returning seems like a compelling buy
0 · Reply
Ml55totoag
Ml55totoag Mar. 13 at 3:33 PM
$RGNX 2c and 2f are no good theyll probably end up in wheelchair. 2g iis nothing short of miracle. This kid can bike and play soccer, normal kid, like duchenne is just a bad dream.
1 · Reply
rando321456
rando321456 Mar. 13 at 6:13 AM
$RGNX IDK the more I look at this data the more I like it, maybe I'm delusional. The conversation is really gonna begin shifting imo to 2 and 3 year results, that's where this thing potentially establishes dominance. Using Elevidys as a proxy the treatment is only increasing NSAA by .77 at the mean age of 9, which is basically the mean age Regenx dosed at for phase 1/2. Despite this later dosing RGX-202 is showing NSAA gains of 2-3 at 12 months. This even extends to the older dose level 1 patients. Obviously it's pretty hard to do a 1-1 as we're talking about 10 patients on 202's side and 50 patients on Elevidy's side, still very promising. I'll be super interested in seeing if the decline in the one patient that was dosed above 10 levels out at 18 and 24 months, no therapy is 100% effective but one thing I liked about the 18 month data drop is that the decliner in that one leveled out.
1 · Reply
Ml55totoag
Ml55totoag Mar. 12 at 11:56 PM
$RGNX senator Johnson is now onboard makary cant play game anymore.
0 · Reply
11thestate
11thestate Mar. 12 at 6:30 PM
With all the buzz around $RGNX , we dug up something interesting. Here's a look at the investor lawsuit they faced following major disclosures about their RGX-111 gene therapy program. Given everything happening now, it's worth checking out — for the full context: https://11th.com/cases/regenxbio-investor-suit
1 · Reply
biotechdeepvalue
biotechdeepvalue Mar. 12 at 5:50 PM
$RGNX does anyone have any thesis on a buyout?
1 · Reply
biotechdeepvalue
biotechdeepvalue Mar. 12 at 5:37 PM
$RGNX I think we are where $CAPR were 9 months ago. As long as pivotal data is clean, we have hope
0 · Reply
whatabigcockyouhave
whatabigcockyouhave Mar. 12 at 4:24 PM
$RGNX load $1 puts, they’re cheap af and that’s where this stock ends up. 70% swing is MINIMUM on binary events like this, we’re not just talking a phase 1,2,3 trial here. we’re talking about the company put everything they had behind this and it’s going to fail. equate it to tesla not being able to make a car, or to nvidia not being able to make a chip. when you look at it through a lenses like that, it becomes obvious to me, short the fuck out of it🤷🏻‍♂️
1 · Reply
Steve_TheBull_Rogers
Steve_TheBull_Rogers Mar. 12 at 3:52 PM
$ALDX Longs I now have the chance of a CRL at 99.2% That's the highest rate of rejection I've done since $RGNX You can either take your profits here or loose it all at 40-60c a share The company has less than 34M left in cash. Market cap is 297M Do the math
4 · Reply
mv21970
mv21970 Mar. 12 at 12:38 PM
$BHVN great article about how the FDA is denying much needed medications and destroying the development of rare disease drugs: https://www.biospace.com/fda/opinion-rare-disease-patients-cant-wait-for-regulatory-process After reading this and remembering what Makary recently said on CNBC about faster approvals and flexibility blabla, he should be fired immediately for lying to the public. I guess both guys are proud and calling themselves genius when patients die and they deny them the only possible therapy, f*ing morons $CAPR $RGNX $QURE $BHVN
1 · Reply
Ml55totoag
Ml55totoag Mar. 12 at 4:06 AM
$RGNX Sgt-003 for 7 to 11yo, elevydis 4-11yo , rgx-202 1-11yo. This means Rgnx will have to eat first and they’ll eat the left over if there’s any lef. 202’s data is excellent. I can’t find functional data for sgt003 it just says “potential” meanwhile 202 dose level 1 effecacy is sustained nssa is +5.6 above control for 2 yrs.
1 · Reply
mikesterz7
mikesterz7 Mar. 11 at 11:20 PM
$RGNX The investigational gene therapy RGX-202 exhibited a favorable safety profile with no serious adverse events and no evidence of liver injury.
0 · Reply
StocktwitsNews
StocktwitsNews Mar. 11 at 10:36 PM
Regenxbio Says Its Gene Therapy For Muscle Disorder Showed No Evidence Of Liver Injury In Study $RGNX $VTI $IWM https://stocktwits.com/news/equity/markets/regenxbio-says-gene-therapy-for-muscle-disorder-showed-no-evidence-of-liver-injury/cZdrXoHRIBT
0 · Reply
rando321456
rando321456 Mar. 11 at 8:26 PM
$RGNX Am I missing anything on the data? Obviously we can look at the timed function tests, but I think NSAA is the gold standard in DMD no? How is this data drop not massively derisking for the pivotal? Lets say the FDA shoots down 202's AA aswell, surely Regenx could simply partner this therapy and run a randomized global trial right? At the current market cap Regenx does not need this thing to be a blockbuster in 12 months, it just needs an agreed upon regulatory pathway and the means to fund it.
2 · Reply